Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Tyrosine kinase inhibitors (TKIs) are first-line therapy for EGFR-mutant non-small cell lung cancer (NSCLC), but resistance limits efficacy.
• Cell division cycle-associated protein 3 (CDCA3) is implicated in adenocarcinoma (LUAD) and chemotherapy sensitivity.
• The role of CDCA3 in EGFR-mutant LUAD and response to TKIs remains unclear.

Purpose of the Study:

• To investigate the association between CDCA3 levels and EGFR-mutant LUAD.
• To determine the correlation between CDCA3 expression and TKI response in NSCLC.
• To explore strategies for enhancing TKI efficacy by modulating CDCA3 levels.

Main Methods:

• Analysis of CDCA3 protein levels in a small-cohort tissue microarray of LUAD.
• Evaluation of CDCA3 expression in an in vitro panel of LUAD cell lines.
• Investigation of CDCA3 regulation by receptor tyrosine kinase signaling and casein kinase 2 (CK2).
• Assessment of TKI response in cells with manipulated CDCA3 levels or CK2 activity.

Main Results:

• CDCA3 protein levels are elevated in EGFR-mutant NSCLC, linked to increased protein stability.
• Higher CDCA3 expression in EGFR-mutant NSCLC correlates with enhanced sensitivity to TKIs.
• Overexpression of CDCA3 or inhibition of CK2 (using CX-4945) upregulates CDCA3 and improves TKI response in resistant NSCLC models.

Conclusions:

• CDCA3 is a potential biomarker for TKI response in EGFR-mutant NSCLC.
• Elevated CDCA3 levels confer sensitivity to TKIs, while strategies to increase CDCA3 may overcome resistance.
• Targeting CDCA3 stability or expression could represent a novel therapeutic strategy for NSCLC patients receiving TKIs.